Navigation Links
New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice
Date:7/13/2014

INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data results found that combination therapy was more effective in removing clumps of amyloid-beta protein in the brain – a component that is thought to lead to Alzheimer's disease (AD) – than use of one therapy. These data were presented today at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark by Ron DeMattos, Ph.D., research fellow in the Neuroscience Division at Eli Lilly and Company. The data was also featured by the AAIC in a research media tips sheet.

"This non-clinical study demonstrates that by simultaneously targeting two different steps in the beta-amyloid disease process, researchers can slow the progression of Alzheimer's disease pathology in genetically engineered mice," said Dr. DeMattos. "These results may have a significant impact on the future of Alzheimer's disease therapies as they support the clinical rationale for using future testing of combination therapy against the a-beta protein in the clinical practice."

Alzheimer's disease, the most common form of dementia, causes progressive decline in memory and other aspects of cognition. A number of new investigational mechanisms for the treatment of Alzheimer's disease are currently in development. One type of investigational mechanism, called beta-secretase inhibitors, aims to block the body's ability to produce beta-amyloid protein, a possible component that leads to Alzheimer's disease. The other type of investigational drug is called a beta-amyloid antibody, which target
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Newly Published Survey Shows Drug Shortages Still Have Major Impact on Patient Care
2. Salutron, Inc. Showcases Benefits of Heart Rate Measurement in Activity Monitoring at ShowStoppers and CES 2014
3. MedShape DynaNail Shows Successful Outcomes in High-Risk Patients
4. New Peer-Reviewed Study Shows Mixed Results in ACO Medication Readiness To Achieve Quality, Cost Goals
5. Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment
6. PCMA: CMS Analysis Shows Mail-Service Pharmacies More Affordable Than Drugstores
7. Imaging Shows Long-term Impact of Blast-induced Brain Injuries in Veterans
8. Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
9. Landmark study of more than 27,000 women shows favorable results of Roches CINtec PLUS cytology test
10. InspireMDs MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
11. New Study Shows Promise For First Effective Medicine To Treat Cocaine Dependence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... HAMPTON, N.J. , March 5, 2015 ... MNK ), a leading global specialty biopharmaceutical company, and ... that they have entered into a definitive agreement under ... from a Madison Dearborn -led investor group in ... Subject to customary closing conditions, the parties expect ...
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... "Global Rising Stars Outlook 2015" report to ... diseases are being sought after with fresh vigor as ... field which is poised to bring a paradigm change ... decades is the Stem cell therapy/Regenerative Medicine space. ...
(Date:3/5/2015)... 5, 2015 According to a ... Product (Systems and Disposables), by Type (Invasive, Minimally Invasive, ... and Ambulatory Sites) - Analysis & Global Forecast to ... expected to reach $1,107.4 Million by 2019 from $887.8 ... a CAGR of 4.5% during the forecast period. ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Global Pharma Rising Stars Outlook 2015 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4
... DUBLIN, Calif., June 16 SuperGen Inc.,(Nasdaq: ... to the discovery, rapid,development and commercialization of ... announced at the 13th Congress of the,European ... its JAK2 kinase inhibitor, prevents tumor cell ...
... COGENT-1 Study of CGT-2168 Expands to Europe; Focus ... Gastrointestinal Side Effects of Antiplatelet Therapy, ... Pharmaceuticals,Inc. today announced that the first patient has ... 3 study of its novel combination medicine,CGT-2168. The ...
Cached Medicine Technology:SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation 2European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals 2
(Date:3/5/2015)... York (PRWEB) March 05, 2015 Testosterone ... who allegedly suffered heart attacks, strokes and other serious ... testosterone therapies continue to move forward in the federal ... District of Illinois. According to a Case Management Order ... procedures for the use of master pleadings in the ...
(Date:3/5/2015)... 2015 Central Nebraska Imaging (CNI) is ... the brand’s new logo and optimized website. ... modern approach to expert diagnostic imaging, centered on patient ... built to be a resource for Nebraska patients and ... forms, communication and referral functionality, video content and resources ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Rhode Island Medical ... year in a row to support the Providence College (PC) ... donation covered the purchase of the ‘Think Pink’ uniforms, which ... Big East Conference opponent DePaul University at Alumni Hall/Mullaney Gymnasium ... continue our support of the PC women’s basketball’s ‘Pink Out’ ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... this March with extra savings on their ... important of health and nutrition, HomeCEUConnection.com is ... using the promo code, NUTRITION2015 . ... Professionals , HomeCEUConnection.com provides high-quality continuing ...
(Date:3/5/2015)... Tempe, AZ (PRWEB) March 05, 2015 ... in various kinds of income to the Arizona economy ... , The report, Demonstrating the Economic Value of Maricopa ... on investment of the Maricopa district in fiscal year ... Economic Modeling Specialists International (EMSI), an organization that ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 3
... statement by,SEIU President Andy Stern:, "Paula Hall -- ... and all her savings when she got sick and ... "Samara Knight -- a nursing assistant from Cleveland, Ohio, ... and the,medication her son needs -- will vote today., ...
... Inc. (Nasdaq:,CYBX) today announced that the company will report ... of its fiscal year ending April,24, 2009 on Wednesday, ... will,conduct a conference call to discuss those results on ... Year 2009 Second Quarter Results Conference Call Instructions, ...
... year,s Gold Sponsor of the Harvard Business School Health Conference. ... Center, Harvard Medical School, November 6 - 8, 2008. , ... ... International, Inc. , the world,s leading manufacturer and distributor of automated ...
... PALO ALTO, Calif., Nov. 4 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... at three upcoming investor conferences., On Tuesday, November ... Saks,Jazz Pharmaceuticals, CEO, will provide a corporate presentation at ... York City., On Wednesday, November 12, 2008 at ...
... U.S. Product Will Be Sold by A Uniquely-Trained Sales ... ... ProStrakan Group plc,(LSE: PSK) today announced that SANCUSO(R) (Granisetron Transdermal System),is now ... United States. Sancuso was approved by,the U.S. Food and Drug Administration (F.D.A.) ...
... vaccination rates far below goals, study finds , , TUESDAY, ... with asthma and other high-risk illnesses are getting flu ... rates from 1992 to 2002 for 18,703 adolescents with ... , During the study period, vaccination rates improved, but ...
Cached Medicine News:Health News:Today We Must Be the Change We Need 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results 2Health News:Lifeclinic International Lead Sponsor at Harvard Business School Health Conference 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3Health News:Too Many High-Risk Teens Not Getting Flu Shots 2
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Medicine Products: